Trillium Therapeutics (NASDAQ:TRIL) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.
This table compares Trillium Therapeutics and Aeterna Zentaris’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Trillium Therapeutics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for Trillium Therapeutics and Aeterna Zentaris, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Trillium Therapeutics presently has a consensus target price of $22.00, suggesting a potential upside of 100.55%. Given Trillium Therapeutics’ higher probable upside, equities research analysts plainly believe Trillium Therapeutics is more favorable than Aeterna Zentaris.
Earnings and Valuation
This table compares Trillium Therapeutics and Aeterna Zentaris’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Trillium Therapeutics||$120,000.00||9,417.84||-$41.62 million||($1.38)||-7.95|
|Aeterna Zentaris||$530,000.00||130.09||-$6.04 million||N/A||N/A|
Aeterna Zentaris has higher revenue and earnings than Trillium Therapeutics.
Insider and Institutional Ownership
67.5% of Trillium Therapeutics shares are held by institutional investors. Comparatively, 2.4% of Aeterna Zentaris shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Trillium Therapeutics beats Aeterna Zentaris on 8 of the 11 factors compared between the two stocks.
About Trillium Therapeutics
Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.
About Aeterna Zentaris
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maximilians-University Wuerzburg for the development of an oral prophylactic bacterial vaccine against COVID-19 disease; development, manufacture, and commercialization of targeted immunosuppressive therapeutic proteins for the treatment of neuromyelitis optica spectrum disorder. It also has a license agreement with Consilient Health Ltd. and Novo Nordisk Biopharm Limited for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.